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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed psychiatric disorder in childhood, with a prevalence of 4-12%, though symptoms often persist into adulthood (1) (2) (3) . Though there is a substantial genetic component to ADHD risk, multiple environmental factors and gene-environment interactions have been identified (4-6). ADHD is a sexually dimorphic condition with boys being 2-3 times more likely to receive a diagnosis (7) . Sex hormones can modify brain development (8) and may explain the male-skewed risk of certain neurodevelopmental disorders. Brain regions involved in ADHD, such as the hippocampus, prefrontal cortex, striatum and amygdala, are influenced by sex hormone signaling during development (9, 10) . ADHD often co-occurs with autism spectrum disorders (ASD), another maleskewed disorder, and the two conditions may share causal pathways (11) . Although increased exposure to prenatal androgens has been noted in ASD (12), the relationship between prenatal hormones and ADHD risk has not been explored.
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of childbearing age, affecting 5-15% of women and characterized by hyperandrogenism, ovarian dysfunction, and polycystic ovarian morphology (13) .The causes of PCOS are not clear but there is evidence for a genetic susceptibility to the disorder (14) . Some studies support an interaction between genetic susceptibility and the influence of maternal environment, including in utero exposure to excess androgens, in the etiology of PCOS (15, 16) . Furthermore, weight gain and obesity are of importance for the development of PCOS.
Obesity is closely related to hyperinsulinemia that enhances hyperandrogenemia in women with PCOS (17) . Hyperandrogenism in turn contributes to adiposity, insulin resistance, and hyperinsulinemia that are common in PCOS (13, 18) . PCOS often emerges during puberty, but it may also develop later in reproductive years, for instance as a result of weight gain (13, 19) . Maternal PCOS is a potential source of excess androgen exposure for the fetus (20, 21) . Maternal diagnosis of PCOS is associated with increased risk of ASD in the offspring, particularly in obese mothers (22) . We hypothesized that maternal PCOS may also influence the offspring's risk of ADHD.
Here we test this hypothesis by examining the relationship between maternal diagnosis of PCOS and the risk of clinically diagnosed ADHD in the offspring in a Swedish nationwide case-control study using prospectively collected health register data. We explored whether high levels of comorbidity between ADHD and ASD could explain this relationship.
Methods

Study population
We used similar methods for the population selection and statistical methods as in our recent study that examined the relationship between maternal diagnosis of PCOS and the risk of offspring ASD (22) . All data are derived from linkages held by Statistics Sweden and the National Board of Health and Welfare, containing routinely collected health and sociodemographic data on the entire population of Sweden and cross-linked via each resident's unique national registration number (23) . The eligible study population consisted of all individuals born in Sweden 1984-2011 and followed until December 31, 2011. We matched all cases of ADHD (see below) in the study population with up to 10 living controls who were without an ADHD diagnosis at the end of follow-up period. Controls were matched by sex and birth month/year. After exclusion of children not born in Sweden, born after 2008, from a multiple birth, adopted, and those with missing covariate data (Figure 1 ), the final sample consisted of 58 912 ADHD cases matched to 499 998 controls, with a case:control ratio between 1:2 to 1:10. This study was approved by the regional ethical review board at Karolinska Institutet. Informed consent was not required for the analysis of anonymized register data.
ADHD case ascertainment
We used a previously validated, two-step approach for identifying cases of ADHD (24) . First, ADHD case status as of December 31, 2011, was defined as a recorded diagnosis of ICD-10: F90 and ICD-9: 314 within the National Patient Register (NPR). The NPR provides data on inpatient care since 1973 and outpatient specialist physician care since 2001. The coverage of the NPR is ~99% of all somatic discharge diagnoses, and the validity of the diagnoses is generally high (25) . As a second step, we We explored whether obstetric complications influenced the findings of our main analysis, due to reports of increased obstetric complications in mothers with PCOS (28) and associations of obstetric complications with ADHD (29) . Apgar score at five minutes was categorized as <7 or ≥7 and supplemented by Apgar score at one minute when data on Apgar score at five minutes were not available. Size for gestational age was categorized as small for gestational age or not. Preterm birth was categorized as <37 weeks or not. Pre-eclampsia was classified according to: ICD-8: 637.03-637.04, 637.09-637.10, ICD-9: 642E-642H and ICD-10: O14-O15 diagnoses recorded within the MBR, or in the NPR during the nine months before and one month after birth of the index child. Birth order was categorized as first-born or not according to the MBR.
Obesity and other features of the metabolic syndrome are common in PCOS and are related to more severe hyperandrogenemia in women with PCOS (30, 31) . Furthermore, elevated maternal body mass index (BMI) has been associated with the risk of ADHD (32) . Thus, we explored the influence of pre-pregnancy BMI and metabolic syndrome on the relationship between maternal PCOS and offspring ADHD.
To calculate maternal baseline BMI (kg/m 2 ) we used weight and height data recorded at the first visit to a maternal health clinic (33) . Data were available for 71% of the mother-child pairs in our analytical sample 
Statistical Analysis
Analyses were performed using SPSS, version 20 (IBM, Armonk, N.Y.). Conditional logistic regression was used to evaluate the association between maternal diagnosis with PCOS and offspring ADHD, first as an unadjusted estimate (Model 1), and then in a model adjusted for maternal/paternal age, parental psychiatric history, parental income/education, birth order and maternal country of birth (Model 2).
Mothers without PCOS were used as the referent group. To explore the influence of obstetric complications on the maternal PCOS/offspring ADHD relationship, we used a model additionally adjusted for the following obstetric factors: Apgar score, preterm birth, small for gestational age, and pre-eclampsia (Model 3). Results were examined for the total analytical sample, in sex-stratified models, and in the metabolic sub-cohort ( Figure 1 ). For the metabolic sub-cohort, we additionally adjusted for maternal BMI in early pregnancy (Model 4).
Since ASD is often diagnosed with ADHD and maternal PCOS may increase risk of ASD (22), we tested whether associations observed between maternal PCOS and offspring ADHD were driven by the comorbidity between the disorders by stratifying ADHD cases on the basis of comorbid ASD and their controls ( Figure 1 ) and repeating the analysis of maternal PCOS (Model 1-3 ).
Lastly, we tested for the effects of worsening cardiometabolic risk profiles amongst women with PCOS.
We explored whether the risk of offspring ADHD was different amongst mothers with the following a priori defined, mutually exclusive categories: no PCOS (referent), PCOS, PCOS with overweight, PCOS with obesity, and PCOS with obesity and indications of metabolic syndrome. Mothers without PCOS were used as the referent group (including women without PCOS but affected by overweight, obesity, diabetes, or essential hypertension).
Sensitivity analyses
Because it is possible that cases ascertained by prescription drug records only may differ from those cases with a recorded diagnosis, we excluded cases ascertained by PDR records only and repeated Models 1-3.
PCOS increases risk of infertility and fertility treatments might influence offspring health; therefore, we repeated the analysis for children born after 1995 (27 194 cases and 227 324 controls), with further adjustment of Model 2 for use of fertility treatment.
Because migrants to Sweden may experience differential access to care and thus be less likely to receive diagnoses of ADHD or PCOS, we excluded all children with mothers born outside of Sweden and repeated models 1-3 for the remaining 52 411 cases and 379 071 controls.
Since information on mothers' medication use during pregnancy was available only for a subsample of children born 2005-2008, we tabulated cases and controls exposed to maternal PCOS and valproate, antipsychotics, spironolactone, or metformin use during pregnancy without further analyses.
Finally, to assess whether more detailed information on parental psychiatric history influenced the relationship between maternal PCOS and offspring ADHD, Model 2 was repeated including the following specific diagnoses in the mother and father: affective disorders (bipolar), non-affective psychosis, ADHD, and other psychiatric diagnoses.
Results
A higher proportion of mothers of ADHD cases had a diagnosis of PCOS compared to mothers of noncases (Table 1) . ADHD cases were more likely to have younger parents, a mother born in Sweden, parental history of psychiatric care, lower household income, lower parental education, obstetric complications, and to be second-born or later.
Maternal diagnosis of PCOS was associated with higher odds of ADHD in both unadjusted (Model 1 OR 1.75, 95% CI 1.58-1.95) and adjusted models (Model 2 OR 1.42, 95% CI 1.26-1.58, Table 2 ). Further adjustment for obstetric complications did not substantially attenuate the OR for ADHD. Excluding cases of ADHD with co-morbid ASD attenuated the associations between maternal PCOS and offspring ADHD (Model 2 OR 1.34, 1.18-1.52), and the ORs were somewhat higher for ADHD with co-morbid ASD (Model 2 OR 1.76, 95% CI 1.37-2.26, Table 2 ). In sex-stratified analyses, ORs tended to be higher amongst girls compared to boys (Table 3) .
Among mothers with PCOS, 1.8% were underweight, 39.1% normal weight, 32.4% overweight and 26.7% obese in early pregnancy. Corresponding proportions among mothers without PCOS were 3.7%, 67.7%, 20.9% and 7.7%, respectively. Maternal PCOS was associated with higher odds of ADHD in the subset of women with BMI data; estimated ORs were similar compared to the whole study sample (Supplementary Table S1 ). The ORs were attenuated after adjustment for BMI (Model 4 OR 1.25, 95% CI 1.09-1.43, Supplementary Table S1 ). In stratified analysis, we observed the highest odds of offspring ADHD among obese women with PCOS and symptoms of the metabolic syndrome (Table 4 ). Trend analysis indicated that odds of ADHD increased with worsening cardiometabolic profiles ( [2005] [2006] [2007] [2008] in the study population, no cases were exposed to maternal PCOS and maternal use of valproate, antipsychotics, or spironolactone during gestation. Three control individuals were exposed to both maternal PCOS and metformin; no control individuals were exposed to any of the other listed medications and maternal PCOS.
Discussion
Maternal diagnosis of PCOS increased the risk of clinically diagnosed ADHD in the offspring even after adjustment for potential confounders. The increase in risk of ADHD remained after excluding cases with comorbid ASD indicating that maternal PCOS increases the risk for ADHD independent of co-morbidity between ADHD and ASD. Our results show that the risk for ADHD grew higher with worsening cardiometabolic profiles amongst mothers with PCOS, such that children of mothers affected by PCOS, obesity and other features of the metabolic syndrome had a greater than two-fold increased risk of ADHD.
To our knowledge, no previous study has examined the relationship between maternal PCOS and offspring ADHD. PCOS is the leading cause of anovulatory infertility and prior studies have found a relationship between fertility treatments, particularly ovulation induction, and offspring ADHD (40, 41).
Recent evidence suggests that the risk associated with fertility treatments originates from the underlying causes of infertility rather than the treatment itself (40) .
Maternal PCOS increased the risk of ASD in a recent study (22) , and our results indicate that ADHD is associated with maternal PCOS independent of co-morbidity with ASD. Taken together, these results suggest that maternal PCOS may have broader detrimental effects on neurodevelopment. We hypothesize that these effects may be mediated by excess prenatal androgen exposure. Most women with PCOS have clinical hypernadrogenemia that is aggravated by obesity (42, 43). During pregnancy, women with PCOS display increased circulating androgen levels (21). Placentas of women with PCOS show abnormal steroidogenesis and increased capacity for producing androgens (20) . Newborns of women with PCOS have atypical levels of sex steroids, including elevated androgens (44, 45).
Prenatal exposure to sex hormones may influence neurodevelopment and increase susceptibility for ADHD through a range of mechanisms. During neurodevelopment, steroids influence the formation of brain regions (9, 10, 46) and neurological processes, including the reward system, motor function and spatial memory (46-48), that are impaired in ADHD. Fetal testosterone levels are linked to abnormal brain lateralization and reduced volume of the right hemisphere, as seen in ADHD (49-51). Fetal steroids influence neuronal spine density and synaptic plasticity that also appear aberrant in ADHD (52, 53).
Aberrations in brain dopaminergic activity, a major biological underpinning of ADHD, have been related to prenatal sex hormone exposure in animal models (54, 55). Maternal polymorphisms in the sex steroid pathway have been associated with inattention and disruptive behavior in boys (56) . Somewhat surprisingly, the risk associated with PCOS appeared slightly elevated for girls compared to boys, though the risk estimates for boys and girls overlapped.
We observed that maternal PCOS was associated with somewhat higher risk of ADHD with co-morbid ASD compared to ADHD only. There has been an increasing focus on the co-morbidity between ADHD and ASD in recent years. Overlap between the disorders has been noted in terms of shared risk factors, similarities in brain structure, and shared dimensions of each disorder (11, (57) (58) (59) . Given the possibility that ADHD with co-morbid ASD represents a distinct sub-type of ADHD, current DSM-V guidelines allow for clinicians to make an ASD diagnosis in the context of ADHD (57, 60) . To date, more research has been conducted regarding hormone exposures in the prenatal environment for ASD compared to ADHD (12). Our study adds further evidence of shared risk factors for these disorders, and highlights the utility of considering co-morbid diagnostic status as the relationship between the prenatal environment and neurodevelopmental outcomes may vary by sub-types of each disorder.
In addition to androgen excess, there are a host of metabolic disturbances concomitant with PCOS, including adiposity, insulin resistance and hyperinsulinemia (13) . Prenatal exposure to maternal overweight/obesity (32, 61) and hyperinsulinemia (62) have been associated with the risk of offspring ADHD. In our study, adjusting for BMI attenuated, but did not fully explain, the relationship between PCOS and the risk of ADHD in our study, indicating that some of the risk could be attributed to elevated BMI in mothers with PCOS. Recent evidence suggests that the association between maternal elevated BMI and ADHD could be due to confounding by time-stable familial factors (32) . The hormonal and metabolic disturbances associated with PCOS would be conserved over time within mothers, and thus we were not able to use family-based study designs to parse this question further. We observed a trend of increasing risk for ADHD with worsening cardiometabolic risk profiles of mothers with PCOS. Mothers with PCOS, obesity, and other features of the metabolic syndrome had the highest risk. In women with PCOS, the androgen excess collaborates with insulin resistance and hyperinsulinemia in increasing adiposity and risk for the metabolic syndrome, which in turn exacerbate hormonal disturbances of PCOS in a positive feedback loop (43, 63). As a result, obese women with PCOS have more severe hyperandrogenemia and metabolic disturbances as compared to their normal-weight counterparts (31, 63) . Apart from maternal hyperandroenemia, maternal obesity and hyperinsulemia also influence the hormonal and metabolic environment of the fetus by modulating placental aromatase activity and potentially by modulating fetal steroidogenesis and gonadal programming (64) (65) (66) . Maternal obesity and the metabolic syndrome also increase circulating levels of inflammatory factors; maternal inflammation has been proposed to play a role in the development of ADHD and ASD (67) (68) (69) . Further studies measuring biomarkers of the hormonal, inflammatory, and metabolic environment of the mother and fetus are necessary to understand the mechanisms linking maternal PCOS to ADHD and its sub-types in the offspring.
Genetic factors related to risk of PCOS and risk of ADHD may explain some of the associations observed in this study. A small clinical study compared ADHD rating scales scores among women with PCOS and healthy controls and found the former to have more ADHD symptoms (70) , indicating that there may be some shared genetic risk between the two disorders. We observed little evidence that the association is explained by increased risk of obstetric complications amongst mothers with PCOS.
Strengths of our study are the large, population-based sample within a publicly-funded universal access healthcare setting, prospectively collected outcome data and information on many potential confounders.
Our study has a number of limitations. The observed prevalence of PCOS was lower than previous estimates, suggesting that PCOS may be unrecognized in many Swedish women. While register-based diagnoses are objective and not subject to recall bias, we might have captured women with more severe PCOS as exposed and thus our findings may not be generalizable to all women with PCOS. Likewise, case ascertainment was based on registered diagnoses and drug treatment for ADHD, and may reflect more severe cases. Data on mothers' medication during pregnancy was available only for a small subsample of the study population. Thus, it was not possible to examine whether pharmacological interventions for mothers with PCOS, such as metformin use, could attenuate risk. Further, it is not possible to rule out that valproate or antipsychotics use during pregnancy might confound the relationship between maternal PCOS and offspring ADHD. In this study, there was little evidence of use of these medications during pregnancy among mothers with PCOS for the subsample of children born 2005-2008.
The question of whether maternal medication use modulates the risks of neurodevelopmental disorders in the offspring associated with maternal PCOS remains an important goal for future research in this area.
Data on BMI were available only for a subsample of the study population. However, there are few differences between women with and without baseline BMI data in characteristics such as socioeconomic factors, suggesting that the BMI data are missing at random (33) .
Conclusion
Maternal PCOS may subtly influence the neurodevelopment of the offspring, resulting in increased risk of neurodevelopmental disorders such as ADHD. The apparent risk increased with worsening maternal cardiometabolic profiles. Encouraging women with PCOS to begin pregnancy at a healthy weight and to adhere closely to gestational weight gain guidelines could potentially decrease the risk of ADHD for their offspring. Given the impact that ADHD has globally, there is a need for delineation of the mechanisms underlying the relationship with maternal PCOS, particularly the role of prenatal androgens and metabolic disturbances in the etiology of neurodevelopmental disorders. 
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